Biologics and Novel Therapeutics in Food Allergy

Brent Anderson; Claire Pascal; M Gohazrua K Butler; Andrew R Chin; Andrew J Long; Sayantani B Sindher; Aikaterini Anagnostou; Stefania Arasi; Philippe Bégin; Christina E Ciaccio; Thomas Eiwegger; Alessandro Fiocchi; David M Fleischer; Maria Garcia-Llorett; Edwin H Kim; Stephanie Leonard; Zahida Rani Maskatia; Kirsten P Perrett; Wayne Shreffler; Julia Upton; R Sharon Chinthrajah

doi:10.1016/j.jaip.2026.01.044

Biologics and Novel Therapeutics in Food Allergy

Brent Anderson
, Claire Pascal
, M Gohazrua K Butler
, Andrew R Chin
, Andrew J Long
, Sayantani B Sindher
, Aikaterini Anagnostou
, Stefania Arasi
, Philippe Bégin
, Christina E Ciaccio
, Thomas Eiwegger
, Alessandro Fiocchi
, David M Fleischer
, Maria Garcia-Llorett
, Edwin H Kim
, Stephanie Leonard
, Zahida Rani Maskatia
, Kirsten P Perrett
, Wayne Shreffler
, Julia Upton

R Sharon Chinthrajah

Research output: Journal article (peer-reviewed) › Review article

1 Citation (Scopus)

Abstract

The US Food and Drug Administration approval of omalizumab for the treatment of food allergy has opened the door for therapeutics targeting the underlying mechanisms that drive food allergy. Here we discuss both approved and novel investigational therapeutic strategies targeting these allergic pathways for the treatment of food allergy.

Original language	English
Pages (from-to)	762-770
Number of pages	9
Journal	Journal of Allergy and Clinical Immunology: In Practice
Volume	14
Issue number	4
DOIs	https://doi.org/10.1016/j.jaip.2026.01.044
Publication status	Published - Apr 2026

Keywords

Food Hypersensitivity/immunology
Humans
Biological Products/therapeutic use
Anti-Allergic Agents/therapeutic use
Omalizumab/therapeutic use
United States Food and Drug Administration
United States
Animals
Immunoglobulin E/immunology
Drug Approval

Access to Document

10.1016/j.jaip.2026.01.044

Cite this

Anderson, B., Pascal, C., Butler, M. G. K., Chin, A. R., Long, A. J., Sindher, S. B., Anagnostou, A., Arasi, S., Bégin, P., Ciaccio, C. E., Eiwegger, T., Fiocchi, A., Fleischer, D. M., Garcia-Llorett, M., Kim, E. H., Leonard, S., Maskatia, Z. R., Perrett, K. P., Shreffler, W., ... Chinthrajah, R. S. (2026). Biologics and Novel Therapeutics in Food Allergy. Journal of Allergy and Clinical Immunology: In Practice, 14(4), 762-770. https://doi.org/10.1016/j.jaip.2026.01.044

@article{40509e12da12449ab2a94c84830eea7d,

title = "Biologics and Novel Therapeutics in Food Allergy",

abstract = "The US Food and Drug Administration approval of omalizumab for the treatment of food allergy has opened the door for therapeutics targeting the underlying mechanisms that drive food allergy. Here we discuss both approved and novel investigational therapeutic strategies targeting these allergic pathways for the treatment of food allergy.",

keywords = "Food Hypersensitivity/immunology, Humans, Biological Products/therapeutic use, Anti-Allergic Agents/therapeutic use, Omalizumab/therapeutic use, United States Food and Drug Administration, United States, Animals, Immunoglobulin E/immunology, Drug Approval",

author = "Brent Anderson and Claire Pascal and Butler, \{M Gohazrua K\} and Chin, \{Andrew R\} and Long, \{Andrew J\} and Sindher, \{Sayantani B\} and Aikaterini Anagnostou and Stefania Arasi and Philippe B{\'e}gin and Ciaccio, \{Christina E\} and Thomas Eiwegger and Alessandro Fiocchi and Fleischer, \{David M\} and Maria Garcia-Llorett and Kim, \{Edwin H\} and Stephanie Leonard and Maskatia, \{Zahida Rani\} and Perrett, \{Kirsten P\} and Wayne Shreffler and Julia Upton and Chinthrajah, \{R Sharon\}",

note = "Publisher Copyright: {\textcopyright} 2026 American Academy of Allergy, Asthma \& Immunology",

year = "2026",

month = apr,

doi = "10.1016/j.jaip.2026.01.044",

language = "English",

volume = "14",

pages = "762--770",

journal = "Journal of Allergy and Clinical Immunology: In Practice",

issn = "2213-2198",

publisher = "American Academy of Allergy, Asthma and Immunology",

number = "4",

}

Anderson, B, Pascal, C, Butler, MGK, Chin, AR, Long, AJ, Sindher, SB, Anagnostou, A, Arasi, S, Bégin, P, Ciaccio, CE, Eiwegger, T, Fiocchi, A, Fleischer, DM, Garcia-Llorett, M, Kim, EH, Leonard, S, Maskatia, ZR, Perrett, KP, Shreffler, W, Upton, J & Chinthrajah, RS 2026, 'Biologics and Novel Therapeutics in Food Allergy', Journal of Allergy and Clinical Immunology: In Practice, vol. 14, no. 4, pp. 762-770. https://doi.org/10.1016/j.jaip.2026.01.044

TY - JOUR

T1 - Biologics and Novel Therapeutics in Food Allergy

AU - Anderson, Brent

AU - Pascal, Claire

AU - Butler, M Gohazrua K

AU - Chin, Andrew R

AU - Long, Andrew J

AU - Sindher, Sayantani B

AU - Anagnostou, Aikaterini

AU - Arasi, Stefania

AU - Bégin, Philippe

AU - Ciaccio, Christina E

AU - Eiwegger, Thomas

AU - Fiocchi, Alessandro

AU - Fleischer, David M

AU - Garcia-Llorett, Maria

AU - Kim, Edwin H

AU - Leonard, Stephanie

AU - Maskatia, Zahida Rani

AU - Perrett, Kirsten P

AU - Shreffler, Wayne

AU - Upton, Julia

AU - Chinthrajah, R Sharon

PY - 2026/4

Y1 - 2026/4

N2 - The US Food and Drug Administration approval of omalizumab for the treatment of food allergy has opened the door for therapeutics targeting the underlying mechanisms that drive food allergy. Here we discuss both approved and novel investigational therapeutic strategies targeting these allergic pathways for the treatment of food allergy.

AB - The US Food and Drug Administration approval of omalizumab for the treatment of food allergy has opened the door for therapeutics targeting the underlying mechanisms that drive food allergy. Here we discuss both approved and novel investigational therapeutic strategies targeting these allergic pathways for the treatment of food allergy.

KW - Food Hypersensitivity/immunology

KW - Humans

KW - Biological Products/therapeutic use

KW - Anti-Allergic Agents/therapeutic use

KW - Omalizumab/therapeutic use

KW - United States Food and Drug Administration

KW - United States

KW - Animals

KW - Immunoglobulin E/immunology

KW - Drug Approval

UR - https://www.scopus.com/pages/publications/105034892138

U2 - 10.1016/j.jaip.2026.01.044

DO - 10.1016/j.jaip.2026.01.044

M3 - Review article

C2 - 41956612

SN - 2213-2198

VL - 14

SP - 762

EP - 770

JO - Journal of Allergy and Clinical Immunology: In Practice

JF - Journal of Allergy and Clinical Immunology: In Practice

IS - 4

ER -

Biologics and Novel Therapeutics in Food Allergy

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this